S. W. Macmahon, R. Peto, and J. Cutler, Blood pressure, stroke, and coronary heart disease. Part 1, Lancet, vol.335, pp.765-774, 1990.

R. Collins, R. Peto, and S. W. Macmahon, Blood pressure, stroke, and coronary heart disease. Part 2, Lancet, vol.335, pp.827-838, 1990.

, Antiplatelet Trialists' Collaboration. Secondary prevention disease by prolonged antiplatelet treatment, Brit Med J, vol.296, pp.320-331, 1988.

, Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients, Fibrinolytic Therapy Trialists' (FTT) Collaborative Group, vol.343, pp.311-322, 1994.

, Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy, Lancet, vol.329, pp.1-15, 1992.

, Early breast cancer trialists' collaborative group. Effects of radiotherapy and surgery in early breast cancer

, An overview of the randomized trials, N Engl J Med, vol.333, pp.1444-1455, 1995.

. Management-committee, The Australian therapeutic trial in mild hypertension, Lancet, vol.i, pp.1261-1267, 1980.

A. B. Carter, Hypotensive therapy in stroke survivors, Lancet, vol.i, pp.485-489, 1970.

J. Coope and T. S. Warrender, Randomised trial of treatment of hypertension in elderly patients in primary care, BMJ, vol.293, pp.1145-1151, 1986.

A. Amery, W. Birkenhäger, P. Brixko, C. Bulpitt, D. Clement et al., Mortality results from the European Working Party on High blood pressure in the Elderly trial, Lancet, pp.1349-1354, 1985.

M. Hamilton, E. N. Thomson, and T. Wisniewski, The role of blood pressure control in preventing complications of hypertension, Lancet, vol.i, pp.235-238, 1964.

, Effect of antihypertensive treatment on stroke recurrence, JAMA, vol.229, pp.409-418, 1974.

, Hypertension Detection and Follow-up Program Cooperative Group. Five -year findings of the

, Hypertension Detection and Follow -up Program. I: Reduction in mortality of persons with high blood pressure, including mild hypertension, JAMA, vol.242, pp.2562-2571, 1979.

C. Bulpitt, A. Fletcher, A. Amery, and J. Coope, The hypertension in the very elderly trial (HYVET), Drugs and ageing, vol.5, pp.171-183, 1994.

F. Gueyffier, F. Boutitie, J. P. Boissel, J. Coope, J. Cutler et al.,

S. , P. R. Schron, and E. , INDANA: a meta-analysis on individual patient data in hypertension. Protocol and preliminary results, Thérapie, vol.50, pp.353-362, 1995.

, Multiple Risk Factor Intervention Trial Research Group. -Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results, JAMA, vol.248, pp.1465-77, 1982.

A. Helgeland, Treatment of mild hypertension: a five year controlled drug trial: the Oslo Study, Am J Med, vol.69, pp.725-732, 1980.

. Pats-collaborating-group, Post-stroke Antihypertensive Treatment Study. A preliminary result, Chin Med J, vol.108, pp.710-717, 1995.

. Shep-cooperative-research and . Group, Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP), JAMA, vol.265, pp.3255-3264, 1991.

M. Perry-hjr, M. Smith, W. Mcdonald, and R. H. , Morbidity and mortality in the Systolic Hypertension in the Elderly Program Pilot Study, Stroke, vol.20, pp.4-13, 1989.

B. Dalhöf, L. Lindholm, and L. Hansson, Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP -Hypertension), Lancet, vol.338, pp.1281-1285, 1991.

L. Thijs, H. Celis, and D. L. Clement, Conventional and ambulatory blood pressure measurement in older patients with isolated systolic hypertension: a second progress report on the ambulatory blood pressure monitoring project in the Syst-Eur trial, Blood Pressure Monitoring, vol.1, pp.95-103, 1996.

, Medical Research Council Working Party. MRC Trial of treatment of mild hypertension: principal results, BMJ, vol.291, pp.97-104, 1985.

, Medical Research Council trial of treatment of hypertension in older adults: principal results, BMJ, vol.304, pp.405-412, 1992.

, McFate Smith W, for the US Public Health Service Hospitals Cooperative Study Group, Circ Res, vol.40, pp.98-105, 1977.

H. M. Perry, A. I. Goldman, and M. A. Lavin, Evaluation of drug treatment in mild hypertension: VA -NHLBI feasibility trial, vol.304, pp.267-288, 1978.

, Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg, JAMA, vol.202, pp.1028-1034, 1967.

, Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg, JAMA, vol.213, pp.1143-1152, 1970.

F. W. Wolff and R. D. Lindeman, Effects of treatment in hypertension: results of a controlled study, J Chron Dis, vol.19, pp.227-240, 1966.

, Joint Liaison Committee on Hypertension. Blood Pressure Lowering Treatment Trialists Collaborative Group, ISH Hypertension News, issue.1, p.3, 1995.

A. Froment, La délicate, imparfaite et irremplaçable mesure tensionnelle indirecte. In : De l'hypertension à l'hypertendu, Editions Boehringer Ingelheim, vol.1, pp.19-24, 1985.

, Comité d'experts OMS. L'hypertension artérielle. Organisation Mondiale de la Santé, p.628, 1978.

J. P. Boissel, J. Blanchard, and E. Panak, Considerations for the meta-analysis of randomized clinical trials

, Cont Clin Trials, vol.10, pp.254-281, 1989.

E. H. Ameling and D. F. De-korte, Man in't Veld AJ. Impact of diagnosis and treatment of hypertension on quality of life: a double -blind, randomized, placebo -controlled, cross -over study of betaxolol, J Cardiovasc Pharmacol, vol.28, pp.752-760, 1991.

R. B. Haynes, D. L. Sackett, and D. W. Taylor, Increased absenteeism from work after detection and labelling of hypertensive patients, N Engl J Med, vol.299, pp.741-744, 1978.

A. Froment, Hypertension artérielle. In Cardiologie pour le praticien

J. P. Delahaye and . Éditeur, , 1989.

C. Crouzier, Le marche de l'hypertension en France : évolution quantitative et structurelle de, 1983.

, Université Paris V, mémoire présenté en vue de la délivrance du diplôme d'études spécialisées de pharmacie hospitalière et des collectivités, 1993.

N. M. Kaplan, Misdiagnosis of systemic hypertension and recommendations for improvement, Am J Cardiol, vol.60, pp.1383-1386, 1987.

, A century of arterial hypertension, p.132, 1996.

P. J. Mulrow and M. Moser, A critique of the 1996 World Health Organisation expert committee report on hypertension, J Hypertens, vol.15, pp.683-685, 1997.

H. G. Langford, J. Stamler, S. Wassertheil-smoller, and R. Prineas, All-cause mortality in the Hypertension Detection and Follow-up Program : findings for the whole cohort and for the persons with less severe hypertension, with and without other traits related to risk of mortality, Prog Cardiov Dis, vol.29, pp.29-54, 1986.

J. Ménard, M. Day, and G. Chatellier, Individualised drug therapy: is it time for a change from mass strategy

, Hypertension: Physiology, Diagnosis and Management, pp.3035-3080, 1995.

J. P. Collet, J. P. Boissel, and . Group, Sick population -treated population : the need for a better definition, Eur J Clin Pharmacol, vol.41, pp.267-271, 1991.

R. A. Stallones, The use and abuse of subgroup analysis in epidemiological research, Prev Med, vol.16, pp.183-194, 1987.

C. J. Bulpitt, Subgroup Analysis, Lancet, vol.ii, pp.31-34, 1988.

B. Schneider, Analysis of clinical trial outcomes: alternative approaches to subgroup analysis, Cont Clin Trials, vol.10, pp.176-186, 1989.

M. E. Buyse, Analysis of clinical trial outcomes: some comments on subgroup analyses, Cont Clin Trials, vol.10, pp.187-194, 1989.

J. P. Boissel, Les analyses en sous-groupe : mode d'emploi, La Lettre du Pharmacologue, vol.3, pp.48-51, 1995.

A. Laplanche, C. Com-nougué, and R. Flamant, Ajustement: danger des analyses par sous-groupes, Méthodes statistiques appliquées à la recherche clinique, pp.83-85, 1987.

J. Wilkstrand, I. Warnold, and G. Olsson, Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study, J Am Med Ass, vol.259, pp.1976-1982, 1988.

P. Bolli, F. Burkart, and K. Vesanen, Electrocardiographic changes during antihypertensive therapy in the International Prospective Primary Prevention Study in Hypertension, Hypertension, vol.9, 1987.

J. A. Cutler, J. D. Neaton, and S. B. Hulley, Coronary heart disease and all-cause mortality in the Multiple Risk Factor Intervention Trial: subgroup findings and comparisons with other trials, Prev Med, vol.14, pp.293-311, 1985.

, Hypertension Detection and Follow-Up Program Cooperative Group. Educational level and 5-year allcause mortality in the hypertension detection and follow-up program, Hypertension, vol.9, pp.641-646, 1987.

, Fourth International Study of Infarct Survival) Collaborative Group -ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction, Lancet, vol.345, issue.4, pp.669-685, 1995.

, Second International Study of Infarct Survival) collaborative group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction: ISIS 2, Lancet, vol.2, pp.349-360, 1988.

F. Gueyffier, A. Froment, and M. Gouton, New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit, J Hum Hypertension, vol.10, pp.1-8, 1996.

M. Lièvre and A. Leizorovicz, Treatment of high blood pressure in patients aged over 60 years: lessons from randomized clinical trials, Cardiology in the elderly, vol.3, pp.217-222, 1995.

M. Cucherat and J. P. Boissel, Modèles d'effet et méta-analyse, Thérapie, vol.52, pp.13-17, 1997.

I. Madinier-colombet, Médicaments antithrombotiques dans la prévention cardio-vasculaire: méta-analyse des essais contrôlés randomisés puissants, 1996.

J. P. Boissel, J. P. Collet, M. Lièvre, and P. Girard, An effect model for the assessment of drug benefit: example of antiarrhythmic drugs in postmyocardial infarction patients, J Cardiovasc Pharmacology, vol.22, pp.356-63, 1993.

A. W. Hoes, D. E. Grobbee, and J. Lubsen, Does drug treatment improve survival ? Reconciling the trials in mild to moderate hypertension, J Hypertension, vol.13, pp.805-811, 1995.

F. Gueyffier, F. Boutitie, M. Cucherat, and J. P. Boissel, A rationale for the meta-analyses (overviews) on individual patient data, European Medicines Research: Perspectives in clinical trials, Fracchia GN, Haavisto KH, pp.31-36, 1995.

F. Gueyffier and J. P. Boissel, Analyse critique du recours aux données individuelles en méta-analyse. A propos d'une expérience dans le domaine du traitement médicamenteux de l'hypertension artérielle, Thérapie, vol.52, pp.29-35, 1997.

S. Sharp, S. G. Thompson, and D. G. Altman, The relation between treatment benefit and underlying risk in metaanalysis, BMJ, vol.313, pp.735-738, 1996.

S. Yusuf, D. Zucker, P. Peduzzi, L. D. Fisher, T. Takaro et al., Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration, Lancet, vol.344, pp.563-570, 1994.

. Beta-blocker, Pooling Project Research Group. The Beta-Blocker Pooling Project (B.B.P.P.) : subgroup findings from randomized trials in post infarction, Eur Heart J, vol.9, pp.8-16, 1988.

T. Cornu-c-on-behalf-of-the and . Group, Thrombolysis in acute stroke pooling project (TAS-PP): A prospective pooled individual patient database, Controlled Clinical Trials, vol.15, p.99, 1994.

P. J. Schwartz, A. J. Camm, G. Frangin, M. J. Jansen, D. G. Julian et al.,

, Does amiodarone reduce sudden death and cardiac mortality after myocardial infarction ? The European Myocardial Infarct Amiodarone Trial (EMIAT), Eur Heart J, vol.15, pp.620-624, 1994.

J. A. Cairns, S. J. Connolly, R. Roberts, and M. Gent,

, Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations : CAMIAT, Arrhythmia Trial Investigators, vol.349, pp.675-682, 1997.

F. Gueyffier, F. Boutitie, J. Boissel, S. Pocock, J. Coope et al.,

P. R. Hm and E. Schron, The INDANA Investigators. The effect of Antihypertensive Drug Treatment on Cardiovascular Outcomes in Women and Men. Results from a meta-analysis of individual patient data in randomised controlled trials, Ann Intern Med, vol.126, pp.761-767, 1997.

M. C. Haugh, J. P. Boissel, N. Bossard, M. Gaydarova, F. Gueyffier et al., Clinical Trial Registries: A corner stone in the assessment and dissemination medical knowledge. Feasibility of clinical trial registries in Europe, European Medicines Research, pp.353-359, 1994.

M. Gouton, A. Froment, E. Dumont, F. Gueyffier, and I. Madinier, Etudes de référence en pathologie cardiovasculaire, Editions MSD, 1995.

R. J. Hardy and C. M. Hawkins, The impact of selected indices of antihypertensive treatment on all-cause mortality, Am J Epidemiol, vol.117, pp.566-574, 1983.

, Hypertension Detection and Follow-up Program Cooperative Group. Hypertension Detection and Followup -Letter to the editor, JAMA, vol.244, pp.1317-1318, 1980.

, The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials

F. Gueyffier, J. Boissel, F. Boutitie, S. Pocock, J. Coope et al.,

K. , P. H. Prineas, R. Schron, and E. , The effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence, Stroke, 1997.

K. Kuramoto, S. Matsushita, and M. Murakawi, Prospective Study on the treatment of mild hypertension in the aged, Jpn Heart J, vol.22, pp.75-85, 1981.

A. Leizorovicz, EMIP-FR, a placebo-controlled study evaluating Trimetazidine in the initial treatment of acute myocardial infarction, 1996.

J. P. Boissel, F. Gueyffier, and M. Haugh, Response to "Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 -The perspective of NIH clinical trialists, Controlled Clinical Trials, vol.16, pp.286-288, 1995.

, Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events : final report of the Pooling Project, J Chronic Dis, vol.31, pp.201-306, 1978.

A. Menotti, A. Keys, H. Blackburn, D. Kromhout, M. Karvonen et al., Comparison of multivariate predictive power of major risk factors for coronary heart diseases in different countries : results from eight nations of the Seven Countries Study, 25 year of follow-up, J Cardiovascular Risk, vol.3, pp.69-75, 1995.

, The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials

F. Gueyffier, J. Boissel, F. Boutitie, S. Pocock, J. Coope et al.,

. Schron, Identification of risk factors in hypertensive patients : the contribution of randomised controlled trials through an individual patient data base

A. Froment, Communication personnelle

M. E. Safar, L. Cloarec-blanchard, and G. M. London, Arterial alterations in hypertension with a disproportionate increase in systolic over diastolic blood pressure, J Hypertens, vol.14, issue.2, pp.103-110, 1996.

D. G. Kleinbaum, L. L. Kupper, and H. Morgenstern, Epidemiological research: principles and quantitative methods, 85 SAS user's guide, vol.6, pp.403-507, 1982.

D. R. Cox, Regression models and life-tables, J Roy Stat Soc, vol.34, pp.187-202, 1972.

F. Boutitie, F. Gueyffier, S. J. Pocock, and J. P. Boissel, Analysis of change of the treatment effect over time in the framework of a meta-analysis, Statistics in Medicine, 1998.

L. Wei, J. P. Boissel, F. Gueyffier, F. Boutitie, and M. Cucherat, Identification and prediction of responders to a therapy: (1) a model and its preliminary application to hypertension

D. Levy, P. Wilson, and K. M. Anderson, Stratifying the patient at risk from coronary disease : new insights from the Framingham Heart Study, Am Heart J, vol.119, pp.712-717, 1990.

K. M. Anderson, P. M. Odell, P. Wilson, and W. B. Kannel, Cardiovascular risk profiles, Am Heart J, vol.121, pp.293-298, 1990.

T. E. Raghunathan and I. I. Yoichi, Analysis of binary data from a multicentre clinical trial, Biometrika, vol.80, pp.127-139, 1993.

G. Chatellier and J. Ménard, The absolute risk as a guide to influence the treatment decision-making process in mild hypertension, J Hypertens, vol.15, pp.217-220, 1997.

S. Renaud, D. Lorgeril, and M. , Wine, alcohol, platelets, and the French paradox for coronary heart disease, Lancet, vol.339, pp.1523-1526, 1992.
URL : https://hal.archives-ouvertes.fr/hal-00395771

P. Ducimetière, J. L. Richard, and F. Cambien, Coronary Heart Disease in middle -aged Frenchmen: comparisons between Paris Prospective Study, Seven Countries Study, and Pooling Project, Lancet, pp.1346-1350, 1980.

F. Gueyffier, F. Boutitie, C. Cornu, G. Jullien, P. Poncelet et al., Présentation d'OCTAVE II : une étude épidémiologique en cours en France sur la valeur pronostique ajoutée par la mesure ambulatoire de la pression artérielle, Arch Mal Coeur Vais, vol.89, pp.1381-1388, 1996.

R. Jackson, P. Barham, and T. Maling, The management of raised blood pressure in New Zealand, BMJ, vol.307, pp.107-117, 1993.

P. L. Canner, K. G. Berge, and N. K. Wenger, for the Coronary Drug Project Research Group. -Fifteen year mortality in Coronary Drug Project Patients : long-term benefit with niacin, J Am Coll Cardiol, vol.8, pp.1245-55, 1986.

E. Ambrosioni, C. Borghi, and B. Magnani, The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction, N Engl J Med, vol.332, pp.80-85, 1995.

M. Cucherat, J. P. Boissel, and A. Leizorovicz, for the APSI investigators. Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction, Am J Cardiol, vol.79, pp.587-589, 1997.

, Second Report of the Sixty Plus Reinfarction Study Research Group. -Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction, Lancet, vol.1, pp.64-68, 1982.

, Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism, Lancet, vol.340, pp.873-876, 1992.

S. Schulman, A. S. Rhedin, and P. Lindmaker, A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism, N Engl J Med, vol.332, pp.1661-1665, 1995.

A. Amery, W. Birkenhäger, P. Brixko, C. Bulpitt, D. Clement et al., Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and prior cardiovascular disease in patients over the age of 60, Lancet, vol.ii, pp.589-592, 1986.

P. De-leeuw, Renal function in the elderly : results of the European Working Party on High Blood Pressure in the Elderly trial, Am J Med, vol.90, pp.3-45, 1991.

D. W. Cockcroft and M. H. Gault, Prediction of creatinine clearance from serum creatinine, Nephron, vol.16, pp.31-41, 1976.

J. P. Boissel and F. Gueyffier, High blood pressure and clinical events linked with atherosclerosis

C. Capdeville and F. Zannad, Coronary and cerebrovascular effects of antihypertensive drugs, pp.240-249, 1990.

R. P. Byington, J. W. Jukema, and J. T. Salonen, Reduction in cardiovascular events during pravastatin therapy : pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program, Circulation, vol.92, pp.2419-2425, 1995.

M. R. Law, N. J. Wald, and S. G. Thompson, By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease, Brit Med J, vol.308, pp.367-373, 1994.

J. P. Boissel, Europe : Computerised information for prescribers. The Lancet, on behalf of the Validata Group, vol.338, pp.1513-1514, 1991.

J. P. Boissel and V. Le-groupe, L'information thérapeutique : comment transmettre les données actuelles de la science, Thérapie, vol.49, pp.299-311, 1994.

J. P. Boissel and N. Bossard, Registry of Multicenter Clinical Trials : Eleventh Report, vol.66, pp.368-383, 1989.

J. P. Boissel and N. Bossard, Registry of multicenter clinical trials. Twelfth and thirteenth report -1990 -1991, Thrombosis and Haemostasis, vol.68, pp.752-778, 1992.

N. Bossard and J. P. Boissel, Registry of multicenter clinical trials: 14th and 15th report 1992-93, CCT, vol.17, pp.130-176, 1996.

, Trial summary report software and data base: Specifications and preliminary results, Strang N on behalf of the FICHTRE Group, vol.15, p.77, 1994.

, Effective care in pregnancy and childbirth, 1989.

N. Simon, P. Jolliet, F. Gueyffier, J. P. Tillement, and J. P. Boissel, La Collaboration Cochrane support de l'information thérapeutique, Rev Méd Interne, vol.18, pp.332-335, 1997.

F. Gueyffier and J. P. Boissel, Centre d'Information Thérapeutique". A network for working nationally within the Cochrane Collaboration: the "Groupe Synthèse" network, 1995.

F. Gueyffier, J. Boissel, and M. Haugh, Le Groupe de Revues Cochrane en Hypertension -Présentation et mode d'emploi, Arch Mal Coeur et Vais, vol.90, pp.1159-1163, 1997.

, Compte rendu de la réunion exploratoire Oxford février 1995, Lettre de l'Information Thérapeutique, 19952.

L. A. Stewart and M. J. Clarke, on behalf of the Cochrane Working Group on meta-analysis using individual patient data. Practical methodology of meta-analyses (overviews) using updated individual patient data, Statistics in Medicine, vol.14, pp.2057-2079, 1995.

L. A. Stewart and M. Parmar, Meta-analysis of the literature or of individual patient data: is there a difference ?, Lancet, vol.341, pp.418-422, 1993.

F. Gueyffier, J. P. Boissel, and F. Boutitie, on behalf of the INDANA Steering Committee. What could be expected from systematic reviews on individual patient data ? Examples from hypertension treatment, 1997.

J. P. Boissel, M. Cucherat, and F. Gueyffier, Place de la méta-analyse dans la définition de la population cible de la thérapeutique, Thérapie, vol.52, pp.19-27, 1997.

J. P. Boissel, Note sur la nécessaire définition des objectifs thérapeutiques pour une démarche de prescription optimisée, Thérapie, vol.51, pp.287-289, 1996.

F. Gueyffier, J. P. Boissel, and M. Cucherat, Message intégrable, problème central de communication pour l'information thérapeutique, Thérapie, 1996.

L. Wilhelmsen, G. Berglund, and D. Elmfeldt, Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial, J Hypertension, vol.7, pp.561-572, 1987.

. The-ipppsh-collaborative and . Group, Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol : the International Prospective Primary Prevention Study in Hypertension (IPPPSH), J Hypertens, vol.3, pp.379-392, 1985.

G. Berglund and O. Andersson, Beta-blockers or diuretics in hypertension ? A six-year follow-up of blood pressure and metabolic side effects, Lancet, vol.i, pp.744-747, 1981.

, Veterans administration Cooperative Study. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension : II. Results of long-term therapy, JAMA, vol.248, pp.2004-2011, 1982.

C. Lenfant, US initiative to target congestive heart failure, World Hypertension League Newsletter, 1997.

D. Levy, M. G. Larson, R. S. Vasan, W. B. Kannel, and K. Ho, The progression from hypertension to congestive heart failure, JAMA, vol.275, pp.1557-1562, 1996.

N. Bossard, J. P. Boissel, and G. Duru, La hiérarchisation selon leur niveau de preuve des données sources, avant leur intégration dans une synthèse, en matière d'efficacité thérapeutique, Thérapie, vol.51, pp.261-264, 1996.

A. Amery, W. Birkenhäger, P. Brixko, C. Bulpitt, D. Clement et al., Mortality results from the European Working Party on High blood pressure in the Elderly trial, Lancet, pp.1349-1354, 1985.

K. M. Anderson, P. M. Odell, P. Wilson, and W. B. Kannel, Cardiovascular risk profiles, Am Heart J, vol.121, pp.293-298, 1990.

, Antiplatelet Trialists' Collaboration. Secondary prevention disease by prolonged antiplatelet treatment

, Brit Med J, vol.296, pp.320-331, 1988.

N. Simon, P. Jolliet, F. Gueyffier, J. P. Tillement, and J. P. Boissel, La Collaboration Cochrane support de l'information thérapeutique, Rev Méd Interne, vol.18, pp.332-335, 1997.

G. Berglund and O. Andersson, Beta-blockers or diuretics in hypertension ? A six-year follow-up of blood pressure and metabolic side effects, Lancet, vol.i, pp.744-747, 1981.

. Beta-blocker, Pooling Project Research Group. The Beta-Blocker Pooling Project (B.B.P.P.) : subgroup findings from randomized trials in post infarction, Eur Heart J, vol.9, pp.8-16, 1988.

J. P. Boissel and V. Le-groupe, L'information thérapeutique : comment transmettre les données actuelles de la science, Thérapie, vol.49, pp.299-311, 1994.

J. P. Boissel, J. Blanchard, and E. Panak, Considerations for the meta-analysis of randomized clinical trials, Cont Clin Trials, vol.10, pp.254-281, 1989.

J. P. Boissel and N. Bossard, Registry of Multicenter Clinical Trials : Eleventh Report, vol.66, pp.368-383, 1989.

J. P. Boissel and N. Bossard, Registry of multicenter clinical trials, Twelfth and thirteenth report -1990

, Thrombosis and Haemostasis, vol.68, pp.752-778, 1992.

J. P. Boissel, M. Cucherat, and F. Gueyffier, Place de la méta-analyse dans la définition de la population cible de la thérapeutique, Thérapie, vol.52, pp.19-27, 1997.

J. P. Boissel and F. Gueyffier, High blood pressure and clinical events linked with atherosclerosis

J. Atkinson, C. Capdeville, and F. Zannad, Coronary and cerebrovascular effects of antihypertensive drugs, pp.240-249, 1990.

J. P. Boissel, Europe : Computerised information for prescribers. The Lancet, on behalf of the Validata Group, vol.338, pp.1513-1514, 1991.

J. P. Boissel, Les analyses en sous-groupe : mode d'emploi, La Lettre du Pharmacologue, vol.3, pp.48-51, 1995.

J. P. Boissel, Note sur la nécessaire définition des objectifs thérapeutiques pour une démarche de prescription optimisée, Thérapie, vol.51, pp.287-289, 1996.

N. Bossard and J. P. Boissel, Registry of multicenter clinical trials: 14th and 15th report 1992-93, CCT, vol.17, pp.130-176, 1996.

F. Boutitie, F. Gueyffier, S. J. Pocock, and J. P. Boissel, Analysis of change of the treatment effect over time in the framework of a meta-analysis, Statistics in Medicine, 1998.

C. Bulpitt, A. Fletcher, A. Amery, and J. Coope, The hypertension in the very elderly trial (HYVET)

, Drugs and ageing, vol.5, pp.171-183, 1994.

C. J. Bulpitt, Subgroup Analysis, Lancet, vol.ii, pp.31-34, 1988.

M. E. Buyse, Analysis of clinical trial outcomes: some comments on subgroup analyses, Cont Clin Trials, vol.10, pp.187-194, 1989.

J. A. Cairns, S. J. Connolly, R. Roberts, and M. Gent,

A. B. Carter, Hypotensive therapy in stroke survivors, Lancet, vol.i, pp.485-489, 1970.

, Effective care in pregnancy and childbirth

G. Chatellier and J. Ménard, The absolute risk as a guide to influence the treatment decision-making process in mild hypertension, J Hypertens, vol.15, pp.217-220, 1997.

D. W. Cockcroft and M. H. Gault, Prediction of creatinine clearance from serum creatinine, Nephron, 1976.

J. P. Collet, J. P. Boissel, and . Group, Sick population -treated population : the need for a better definition, Eur J Clin Pharmacol, vol.41, pp.267-271, 1991.

R. Collins, R. Peto, and S. W. Macmahon, Blood pressure, stroke, and coronary heart disease. Part 2, Lancet, vol.335, pp.827-838, 1990.

, Comité d'experts OMS. L'hypertension artérielle. Organisation Mondiale de la Santé, 1978.